

STRIDES PHARMA GLOBAL (UK) LIMITED

Registration Number: 09707843

BALANCE SHEET AS AT MARCH 31, 2024

		Amount in GBP	
		31-Mar-24	31-Mar-23
<b>A ASSETS</b>			
<b>I Non-current assets</b>			
(a) Financial assets			
	(i) Investments	1	21,715,863
			19,694,427
	<b>Total non-current assets</b>		<b>21,715,863</b>
			<b>19,694,427</b>
<b>II Current assets</b>			
(a) Financial assets			
	(i) Cash and cash equivalents	2	145,564
			170,429
	(b) Other current assets	3	125,490
			742,226
	<b>Total current assets</b>		<b>271,054</b>
			<b>912,655</b>
<b>TOTAL ASSETS</b>			<b>21,986,917</b>
			<b>20,607,083</b>
<b>B EQUITY AND LIABILITIES</b>			
<b>I Equity</b>			
(a) Equity share capital			
			44,250,749
	(b) Other equity		(29,209,922)
			(29,235,275)
	<b>Total Equity</b>		<b>15,040,827</b>
			<b>15,015,474</b>
<b>II Liabilities</b>			
<b>1 Current liabilities</b>			
(a) Financial liabilities			
	(i) Trade payables	4	4,080
			4,320
	(ii) Other financial liabilities	5	6,876,067
			5,518,845
	(b) Provisions	6	2,500
			5,000
	(c) Other current liabilities	7	63,443
			63,443
	<b>Total current liabilities</b>		<b>6,946,090</b>
			<b>5,591,608</b>
<b>TOTAL EQUITY AND LIABILITIES</b>			<b>21,986,917</b>
			<b>20,607,083</b>

**STRIDES PHARMA GLOBAL (UK) LIMITED**  
**Registration Number: 09707843**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2024**

Particulars	Note No.	Amount in GBP	
		31-Mar-24	31-Mar-23
<b>1</b> Revenue from operations		-	-
<b>2</b> Other Income	8	134,483	15,633
<b>3 Total Revenue (1+2)</b>		<b>134,483</b>	<b>15,633</b>
<b>4 Expenses</b>			
(a) Finance costs	9	727	151
(b) Other expenses	10	20,665	283,146
<b>Total expenses</b>		<b>21,392</b>	<b>283,296</b>
<b>5 Profit / (Loss) before exceptional items and taxes (3-4)</b>		<b>113,091</b>	<b>(267,663)</b>
<b>6</b> Exceptional Item		-	-
<b>7 Profit / (Loss) before taxes (5+6)</b>		<b>113,091</b>	<b>(267,663)</b>
<b>8 Tax Expense:</b>			
Total tax expenses		-	-
<b>9 Profit / (Loss) for the year after tax</b>		<b>113,091</b>	<b>(267,663)</b>
<b>10 Other comprehensive income</b>			
Items that will not be reclassified to profit or loss:		(87,738)	(102,490)
Income tax relating to items that will not be reclassified to profit or loss		-	-
<b>11 Other comprehensive income for the year, net of tax</b>		<b>(87,738)</b>	<b>(102,490)</b>
<b>12 Total comprehensive income for the year</b>		<b>25,353</b>	<b>(370,153)</b>

**STRIDES PHARMA GLOBAL (UK) LIMITED**  
**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED MARCH 31, 2024**

(A) **Called up capital**

Particulars	Amount in GBP
Balance as at March 31, 2023	43,357,438
Changes in capital during the year	-
Balance as at March 31, 2024	43,357,438

(B) **Other equity**

Particulars	Reserves and Surplus		Items of other comprehensive income	Total
	Capital reserve	Retained earnings	Remeasurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2023	-	(29,235,275)		(29,235,275)
Profit/loss for the year	-	25,353	-	25,353
Balance as at March 31, 2024	-	(29,209,922)	-	(29,209,922)

**STRIDES PHARMA GLOBAL (UK) LIMITED**  
**Notes forming part of financial statement**

Note  
No.

1	Non current investments	Amount in GBP	
	Particulars	31-Mar-24	31-Mar-23
	Investments	21,715,863	19,796,917
	<b>Total</b>	<b>21,715,863</b>	<b>19,796,917</b>
2	Cash and cash equivalents	Amount in GBP	
	Particulars	31-Mar-24	31-Mar-23
	Cash in hand	145,564	170,536
	Balances with banks: In current accounts		
	<b>Total</b>	<b>145,564</b>	<b>170,536</b>
3	Other current assets	Amount in GBP	
	Particulars	31-Mar-24	31-Mar-23
	<b>Unsecured, considered good</b>		
	Loans and advances to Group entities	125,490	20,013
	<b>Total</b>	<b>125,490</b>	<b>20,013</b>
4	Trade payables	Amount in GBP	
	Particulars	31-Mar-24	31-Mar-23
	Trade payable	4,080	3,690
	<b>Total</b>	<b>4,080</b>	<b>3,690</b>
5	Other Current financial Liabilities	Amount in GBP	
	Particulars	31-Mar-24	31-Mar-23
	Payable to group entities	6,876,067	5,423,016
	<b>Total</b>	<b>6,876,067</b>	<b>5,423,016</b>
6	Provisions	Amount in GBP	
	Particulars	31-Mar-24	31-Mar-23
	Provision for expenses	2,500	5,000
	<b>Total</b>	<b>2,500</b>	<b>5,000</b>
7	Other current liabilities	Amount in GBP	
	Particulars	31-Mar-24	31-Mar-23
	Tax liabilities	63,443	63,443
	<b>Total</b>	<b>63,443</b>	<b>63,443</b>

**STRIDES PHARMA GLOBAL (UK) LIMITED**  
**Notes forming part of financial statement**

Note

No.

<b>8 Other Income</b>	<b>Amount in GBP</b>	
<b>Particulars</b>	<b>31-Mar-24</b>	<b>31-Mar-23</b>
Dividend Received	119,606	-
Interest Income	14,877	-
<b>Total</b>	<b>134,483</b>	<b>-</b>

<b>9 Finance cost</b>	<b>Amount in GBP</b>	
<b>Particulars</b>	<b>31-Mar-24</b>	<b>31-Mar-23</b>
Bank charges	727	83
<b>Total</b>	<b>727</b>	<b>83</b>

<b>10 Other expenses</b>	<b>Amount in GBP</b>	
<b>Particulars</b>	<b>31-Mar-24</b>	<b>31-Mar-23</b>
Net loss on foreign currency transactions	-	97,103
Professional fees	11,465	630
Payment to Auditors - For Statutory Audit	9,200	6,840
Impairment charge in subsidiaries	-	716,704
<b>Total</b>	<b>20,665</b>	<b>821,277</b>